This inventor holds 1 USPTO granted patent. Top assignee: Cytoskeleton, Inc.. Active years: 2007.
Company Filing History:
Years Active: 2007
Title: Jain Dong Jiang: Innovator in Cancer Treatment
Introduction
Jain Dong Jiang is a notable inventor based in New York, NY (US). He has made significant contributions to the field of cancer treatment through his innovative research and development of novel compounds. His work focuses on the mechanisms of action for anti-tumor tubulin ligands, which play a crucial role in cancer cell dynamics.
Latest Patents
Jain Dong Jiang holds 1 patent for his invention titled "Anti-S-phase tubulin ligands." This invention presents a unique mechanism of action that arrests cancer cells in the S-phase of cell division. The compounds, known as halogenated derivatives of acetamido benzoyl ethyl ester (HAABE), induce cell death through a combination of apoptosis and necrosis mechanisms. Notably, normal cells remain unaffected at the same concentrations of the compound, highlighting the targeted nature of this innovation.
Career Highlights
Jain Dong Jiang is associated with Cytoskeleton, Inc., where he continues to advance his research in cancer therapeutics. His work has demonstrated potent cancericidal activity in tissue culture assays and animal tumor models. The ligands he developed bind covalently to tubulin both in vitro and in vivo, showcasing their effectiveness in targeting cancer cells.
Collaborations
Jain collaborates with talented coworkers, including Ashley Davis and Kim Middleton. Their combined expertise contributes to the innovative research environment at Cytoskeleton, Inc.
Conclusion
Jain Dong Jiang's contributions to cancer treatment through his patented inventions exemplify the impact of innovative research in the medical field. His work not only advances scientific understanding but also holds promise for future therapeutic applications.